Literature DB >> 27660157

Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity.

Nazarii Kobyliak1, Tetyana Falalyeyeva2, Petro Bodnar3, Tetyana Beregova2.   

Abstract

Today probiotics have been suggested as a treatment for the prevention of NAFLD. Omega-3 fatty acid supplementation may have beneficial effects in regulating hepatic lipid metabolism, adipose tissue function and inflammation. The present study was designed to determine whether probiotics plus omega-3 are superior to probiotics alone on the monosodium glutamate (MSG)-induced NAFLD model in rats. We included 60 rats divided into four groups, 15 animals in each. Rats of group I were intact. Newborn rats of groups II-IV were injected with MSG. The III (Symbiter) group received 2.5 ml/kg of multiprobiotic "Symbiter" containing concentrated biomass of 14 probiotic bacteria genera. The IV (Symbiter-Omega) groups received "Symbiter-Omega" combination of probiotic biomass supplemented with flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5 %). In both interventional groups reduction in total NAS score was observed. Supplementation of alive probiotic mixture with omega-3 fatty acids lead to 20 % higher decrease in steatosis score (0.73 ± 0.11 vs 0.93 ± 0.22, p = 0.848) and reduction by 16.6 % of triglycerides content in liver as compared to probiotic alone. Our study demonstrated more pronounced reduction in hepatic steatosis and hepatic lipid accumulation after treatment with combination of alive probiotics and omega-3 as compared to probiotics alone.

Entities:  

Keywords:  Hepatic steatosis; Non-alcoholic fatty liver disease; Omega-3 fatty acids; Probiotics

Mesh:

Substances:

Year:  2017        PMID: 27660157     DOI: 10.1007/s12602-016-9230-1

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  33 in total

Review 1.  Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence.

Authors:  Alessandro Federico; Marcello Dallio; Justyna Godos; Carmela Loguercio; Federico Salomone
Journal:  Transl Res       Date:  2015-08-12       Impact factor: 7.012

2.  Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Ann Med       Date:  2010-11-02       Impact factor: 4.709

Review 3.  Novel opportunities for next-generation probiotics targeting metabolic syndrome.

Authors:  Patrice D Cani; Matthias Van Hul
Journal:  Curr Opin Biotechnol       Date:  2014-10-29       Impact factor: 9.740

4.  Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model.

Authors:  Astrid Reichold; Sibylle A Brenner; Astrid Spruss; Karin Förster-Fromme; Ina Bergheim; Stephan C Bischoff
Journal:  J Nutr Biochem       Date:  2013-11-06       Impact factor: 6.048

Review 5.  Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Helen M Parker; Nathan A Johnson; Catriona A Burdon; Jeffrey S Cohn; Helen T O'Connor; Jacob George
Journal:  J Hepatol       Date:  2011-10-21       Impact factor: 25.083

Review 6.  The role of liver biopsy to assess non-alcoholic fatty liver disease.

Authors:  Nazarii Kobyliak; Ludovico Abenavoli
Journal:  Rev Recent Clin Trials       Date:  2014

7.  Lactobacillus rhamnosus GG improves insulin sensitivity and reduces adiposity in high-fat diet-fed mice through enhancement of adiponectin production.

Authors:  Sun-Woo Kim; Kun-Young Park; Bobae Kim; Eunha Kim; Chang-Kee Hyun
Journal:  Biochem Biophys Res Commun       Date:  2013-01-09       Impact factor: 3.575

8.  Exercise and Omega-3 Polyunsaturated Fatty Acid Supplementation for the Treatment of Hepatic Steatosis in Hyperphagic OLETF Rats.

Authors:  Sarah J Borengasser; R Scott Rector; Grace M Uptergrove; E Matthew Morris; James W Perfield; Frank W Booth; Kevin L Fritsche; Jamal A Ibdah; John P Thyfault
Journal:  J Nutr Metab       Date:  2011-09-12

9.  Effects of Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036 on hepatic steatosis in Zucker rats.

Authors:  Julio Plaza-Diaz; Carolina Gomez-Llorente; Francisco Abadia-Molina; Maria Jose Saez-Lara; Laura Campaña-Martin; Sergio Muñoz-Quezada; Fernando Romero; Angel Gil; Luis Fontana
Journal:  PLoS One       Date:  2014-05-22       Impact factor: 3.240

10.  Short-term periodic consumption of multiprobiotic from childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity.

Authors:  Oleksandr Savcheniuk; Nazarii Kobyliak; Maryana Kondro; Oleksandr Virchenko; Tetyana Falalyeyeva; Tetyana Beregova
Journal:  BMC Complement Altern Med       Date:  2014-07-16       Impact factor: 3.659

View more
  6 in total

Review 1.  Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.

Authors:  Junli Ma; Qihang Zhou; Houkai Li
Journal:  Nutrients       Date:  2017-10-16       Impact factor: 5.717

2.  New insights on strain-specific impacts of probiotics on insulin resistance: evidence from animal study.

Authors:  Nazarii Kobyliak; Tetyana Falalyeyeva; Olena Tsyryuk; Majid Eslami; Dmytro Kyriienko; Tetyana Beregova; Liudmila Ostapchenko
Journal:  J Diabetes Metab Disord       Date:  2020-02-16

3.  Probiotic Composition and Chondroitin Sulfate Regulate TLR-2/4-Mediated NF-κB Inflammatory Pathway and Cartilage Metabolism in Experimental Osteoarthritis.

Authors:  Oleksandr Korotkyi; Alevtina Huet; Kateryna Dvorshchenko; Nazarii Kobyliak; Tetyana Falalyeyeva; Liudmyla Ostapchenko
Journal:  Probiotics Antimicrob Proteins       Date:  2021-01-18       Impact factor: 4.609

4.  Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults.

Authors:  Haijiang Dai; Weijun Wang; Ruifang Chen; Zhiheng Chen; Yao Lu; Hong Yuan
Journal:  Nutr Metab (Lond)       Date:  2017-08-01       Impact factor: 4.169

Review 5.  Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease.

Authors:  Ludovico Abenavoli; Tetyana Falalyeyeva; Luigi Boccuto; Olena Tsyryuk; Nazarii Kobyliak
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-11

6.  Yunpi Heluo decoction reduces ectopic deposition of lipids by regulating the SIRT1-FoxO1 autophagy pathway in diabetic rats.

Authors:  Zhujun Mao; Shiyu Liu; Tao Yu; Jinglan Su; Kefu Chai; Siying Weng
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.